Efficacy and Safety of Tianma Gouteng Decoction in the Treatment of Intracerebral Hemorrhage: A Systematic Review of Randomized Controlled Trials

Abstract

Objective: To systematically evaluate the efficacy and safety of Tianma Gouteng Decoction (TMGTY) in the treatment of intracerebral hemorrhage (ICH). Methods: Eight databases, including CNKI, Wanfang, VIP, China Biomedical, PubMed, Cochrane, EMBASE, and Web of Science, were searched up to February 25, 2023. Two investigators independently screened articles, extracted data, evaluated quality, and performed a systematic review or meta-analysis. Results: 11 randomized controlled trials with 977 patients were included. Compared with conventional treatment alone, the combination of TMGTY with conventional treatment improved NIHSS scores (MD=-3.86, 95% CI: -6.42, -1.31, P=0.003), treatment efficiency (RR=1.19, 95% CI: 1.13, 1.26, P<0.00001), and Barthel Index scores (MD=11.48, 95% CI: 9.71, 13.24, P<0.00001), while reducing complication rates (RR=0.24, 95% CI: 0.13, 0.45, P<0.00001), IL-6 (MD=-11.20, 95% CI: -13.84, -8.57, P<0.00001), and TNF-α levels (MD=-13.88, 95% CI: -16.73, -11.02, P<0.00001). Conclusion: Current clinical evidence suggests that TMGTY combined with conventional treatment is safe and effective in the treatment of ICH, more high-quality randomized controlled clinical trials are needed to validate and support the findings.